Safety and efficacy study of vociprotafib (SAR442720) in combination with other agents in advanced malignancies

Trial Identifier: TCD16210
Sponsor: Sanofi
Collaborator:
Revolution Medicines, Inc.
Mirati Therapeutics,Inc.
Start Date: June 2020
Primary Completion Date: April 2024
Study Completion Date: April 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1019
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1125
ARGENTINA, Buenos Aires BUENOS AIRES, Buenos Aires, ARGENTINA, 1093
ARGENTINA, Santa Fe ROSARIO, Santa Fe, ARGENTINA, 2000
AUSTRALIA, New South Wales SYDNEY, New South Wales, AUSTRALIA, 2031
AUSTRALIA, Queensland WOOLLOONGABBA, Queensland, AUSTRALIA, 4102
AUSTRALIA, Victoria MELBOURNE, Victoria, AUSTRALIA, 3084
CHILE, La Araucanía TEMUCO, La Araucanía, CHILE, 4780000
CHILE, Reg Metropolitana de Santiago SANTIAGO, Reg Metropolitana de Santiago, CHILE, 8420383
CHILE, Valparaíso VIÑA DEL MAR, Valparaíso, CHILE, 2520598
Korea, Republic of, Chungcheongbuk-do CHEONGJU-SI, Chungcheongbuk-do, Korea, Republic of, 28644
Korea, Republic of, Gyeonggi-do SEONGNAM-SI, Gyeonggi-do, Korea, Republic of, 13496
Korea, Republic of, Seoul-teukbyeolsi SEOUL, Seoul-teukbyeolsi, Korea, Republic of, 03722
SPAIN, Madrid MADRID, Madrid, SPAIN, 28040
SPAIN, Madrid MADRID, Madrid, SPAIN, 28050
SPAIN, Valencia VALENCIA, Valencia, SPAIN, 46010
Taiwan TAINAN CITY, Taiwan, 704
Taiwan TAIPEI CITY, Taiwan, 100
UNITED STATES, California ORANGE, California, UNITED STATES, 92868
UNITED STATES, Texas HOUSTON, Texas, UNITED STATES, 77030